Dong-A Pharmaceutical’s premium multi-vitamin “Orthomol” ranked No. 1 in sales in the domestic multi..

사진 확대 Dong-A Pharmaceutical’s multi-vitamin “Oso Mall”. [Dong-A Pharmaceutical Co., Ltd.]

Dong-A Pharmaceutical’s premium multi-vitamin “Orthomol” ranked No. 1 in sales in the domestic multi-vitamin market for the third consecutive year.

Dong-A Pharmaceutical announced on the 31st that Osomol ranked first in multi-vitamin sales based on all online and offline distribution channels from 2023 to 2025, according to a survey by global research company Euromonitor International. The survey was compiled based on all distribution channel sales data, including over-the-counter drugs.

Since entering the domestic market through the launch of its flagship product “Immune” in 2020, Osomol has expanded its product line by introducing “VitalM” and “VitalF” in 2023.

Immun is designed to help maintain normal immune function by containing vitamins B, C, E, niacin, and zinc, and Vital Line is characterized by supporting nutrition management in daily life with up to 23 types of micronutrients including omega-3.

In terms of distribution, offline channels such as H&B stores and department stores, as well as online shopping malls and mobile commerce, have expanded consumer contact points to strengthen competitiveness in all channels.

In particular, the fact that it provides convenience and differentiated experiences by applying a double formulation that combines liquid and tablet, and that it has established a brand image of a “premium health gift” is also considered a growth factor.

“It maintains the research standards of the German headquarters and applies formulation that takes into account the nutritional intake characteristics of Koreans,” a Dong-A Pharmaceutical official said. “We plan to continue to strengthen our brand competitiveness by expanding various formulations and product lines.”

#

Dong-A Pharmaceutical

Multi-Vitamin

Premium

Offline

Orthomol